Cencora stock holds firm after RBC keeps $330 target

Published on 09/08/2026 at 23:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cencora stock stays in view after RBC kept a $330 price target and the latest quarter showed $4.48 adjusted EPS on $84.75 billion in revenue.

Luftbild eines modernen Pharma-Lagerzentrums mit Lieferfahrzeugen und Verladedocks — Cencora Inc. betreibt US15135B1017 ein großes Pharmadistributionszentrum mit Lastwagen Gabelstaplern und täglicher Medikamentenlogistik, Illustration mit AI erstellt.

Cencora Inc. stock (ISIN US15135B1017) traded at $330.52 on the NYSE, with a market capitalization of $62.25 billion and a 52-week range of $244.82 to $377.54 as of September 8, 2026.

RBC keeps its view

Investing.com reported on September 8, 2026 that RBC Capital kept its Sector Perform rating and $330 price target on Cencora. The target sits just below the latest quote, while the shares are still close to the 200-day average of $309.32 reported the same day by MarketBeat.

The latest quarter gives the move context: Cencora reported fiscal third-quarter 2026 adjusted EPS of $4.48 and revenue of $84.75 billion, both above estimates of $4.35 and $84.31 billion, according to MarketScreener on August 5, 2026.

Margins and guidance matter

That quarter also included a 5.1 percent increase in revenue versus the same period a year earlier, while net margin came in at 0.79 percent and return on equity at 125.45 percent, according to MarketBeat. Cencora also kept its fiscal 2026 adjusted EPS guidance at $17.75 to $17.95, which frames the stock around execution rather than a single quarterly beat.

Specialty growth still drives the story

At the Wells Fargo 21st annual healthcare conference on September 8, 2026, Cencora said GLP-1 drugs generated $2.3 billion in third-quarter revenue, up 25 percent year over year, and that the business completed $1 billion in opportunistic share repurchases in the period, according to Investing.com. For investors, that mix keeps specialty pharmaceuticals and capital returns at the center of the story.

One product line

Cencora's specialty pharmaceuticals and GLP-1 exposure remain the most visible operating theme in the latest conference remarks, alongside the Walgreens volume shift that management said was already built into guidance for fiscal 2026, according to Investing.com.

Price level today

Cencora stock stood at $330.52 on September 8, 2026, with the quote near RBC's $330 target and above the 200-day average of $309.32. The market cap was $62.25 billion.